Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330385 | 0.85 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR5A | |
| SCHEMBL26828793 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4HTR2AKDM1A | |
| SCHEMBL23420597 | 0.81 | PRCP (0.42) | SLC6A2SLC6A3SLC6A4HTR2AKDM1A | |
| SCHEMBL4557220 | 0.80 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL6924410 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HTR2AKDM1A | |
| SCHEMBL18761435 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4HTR2AKDM1A | |
| SCHEMBL29581180 | 0.78 | HSD17B1 (0.40) | SLC6A2SLC6A3SLC6A4HTR2A | |
| SCHEMBL18761162 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AKDM1A | |
| SCHEMBL22176765 | 0.73 | OPRM1 (0.34) | SLC6A4HTR2ACYP11B1CYP11B2 | |
| SCHEMBL8251125 | 0.72 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4HTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090292026-A1 | Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine | SEPRACOR INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292026-A1 | Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine | TPH1, PNMT, NAT1 | SLC6A2 6/4885SLC6A3 5/4885SLC6A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.